צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים: Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT) generates revenue from complex genetic testing and reproductive health orders. The quarterly earnings per share shift on GURU.Markets captures the business's resilience, where -121.00 reflects the latest metric level. Fulgent Genetics, Inc. (FLGT) relies on a B2B cloud platform featuring an extensive range of oncology panels and is currently scaling the implementation of AI in data analysis.
פילוחי מדדים פיננסיים ומדדי שוק עבור Fulgent (FLGT)
A comparative asset analysis requires precise measurement of net income per share dynamics. The calculation model updates quarterly EPS growth rates daily, eliminating information gaps between financial reports. This is critical for Fulgent Genetics, Inc. (FLGT) due to declining demand for genetic tests and pricing pressure in oncology diagnostics. The downward trend confirms the risk of business stagnation. By analyzing quarterly EPS fluctuations, an investor can timely identify the threat of a deep price drawdown.
